close

Fundraisings and IPOs

Date: 2011-01-27

Type of information: Private placement

Company: Active Biotech (Sweden)

Investors:

Amount: SEK 375 million before transaction costs.(€ 42,595 million)

Funding type: private placement of 2,500,000 new shares

Planned used:

The proceeds from the Private Placement are intended to be used to strengthen Active Biotech's R&D activities through enabling the Company to fund development of its late stage prostate cancer treatment candidate, TASQ, with potential partners, advancing existing projects further towards commercialization, bringing additional discovery projects into the clinic and for general corporate purposes.

Others:

The private placement, which was announced on 26 January 2011, has allowed Active Biotech to place 2,500,000 new shares at a price of SEK 150 per share with international institutional investors and qualified investors in Sweden through an accelerated bookbuilding procedure. Active Biotech has retained Jefferies International Limited and Carnegie Investment Bank as bookrunners in a private placement of new shares directed towards international institutional investors and qualified investors in Sweden.

Therapeutic area: Autoimmune diseases - Cancer - Oncology

Is general: Yes